PALO ALTO, Calif. (AP) — PALO ALTO, Calif. (AP) — BridgeBio Pharma Inc. (BBIO) on Thursday reported a loss of $140.2 million in its first quarter.
On a per-share basis, the Palo Alto, California-based company said it had a loss of 92 cents.
The results did not meet Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of 84 cents per share.
The rare disease drug developer posted revenue of $1.8 million in the period, also missing Street forecasts. Three analysts surveyed by Zacks expected $7.2 million.
BridgeBio Pharma shares have increased 89% since the beginning of the year. The stock has risen 73% in the last 12 months.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on BBIO at https://www.zacks.com/ap/BBIO
Copyright © 2024 The Associated Press. All rights reserved. This material may not be published, broadcast, written or redistributed.
